TLN1 and prostate carcinoma: A loss of talin1 impairs EMT and decreases cell motility [16], and its overexpression is associated with the malignant biology of various human malignancies, including colorectal cancer [17], prostate cancer [18], triple-negative breast cancer [19], and glioblastoma [20].